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Accepted 5 February 2016Objective: To compare perioperative outcomes between robotic-assisted benign hysterectomies and abdominal,
vaginal, and laparoscopic hysterectomies when performed by high-volume surgeons. Methods: A multicenter
data analysis compared 30-day outcomes from consecutive robotic-assisted hysterectomies performed by
high-volume surgeons (≥60 prior procedures) at nine centers with records retrieved from the Premier Perspec-
tive database for abdominal, vaginal, and laparoscopic hysterectomies performed by high-volume gynecologic
surgeons. Data on benign hysterectomy disorders from January 1, 2012 to September 30, 2013 were included.
Results:Data from 2300 robotic-assisted, 9745 abdominal, 8121 vaginal, and 11 952 laparoscopic hysterectomies
were included. The robotic-assisted patient cohort had a signiﬁcantly higher rate of adhesive disease compared
with the vaginal (P b 0.001) and laparoscopic cohorts (P b 0.001), a signiﬁcantly higher rate of morbid obesity
than the vaginal (P b 0.001) or laparoscopic cohorts (P b 0.001), and a signiﬁcantly higher rate of large uteri
(N250 g) than the abdominal (P b 0.001), vaginal (P b 0.001), or laparoscopic cohorts (P = 0.017). The
robotic-assisted cohort experienced signiﬁcantly fewer intraoperative complications than the abdominal
(P b 0.001) and vaginal cohorts (P b 0.001), and experienced signiﬁcantly fewer postoperative complications
compared with all the comparator cohorts (P b 0.001). Conclusion: When performed by gynecologic surgeons
with relevant high-volume experience, robotic-assisted benign hysterectomy provided improved outcomes
compared with abdominal, vaginal, and laparoscopic hysterectomy.
© 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Comparisons of robotic-assisted hysterectomy with laparoscopic,
abdominal, and vaginal hysterectomy are many [1–3]. Between 2005
and 2013, the percentage of all hysterectomies with benign indications
thatwere performed as abdominal hysterectomies declined from59% to
22%, as reported in the Premier Perspective database (Premier Inc.,
Charlotte, NC, USA) (Fig. 1). Surgeons and patients have increasingly fa-
vored robotic-assisted and laparoscopic approaches over open ap-
proaches owing to the lower perioperative morbidity and shorter
recovery that are associated with these surgeries [4–6]. The da Vincin Regional Medical Center, 75
3; fax: +1 775 327 4611.
logy and Obstetrics. Published bySurgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) received
US Food and Drug Administration clearance in 2005 for use in gyneco-
logic robotic-assisted surgical procedures [7].
Comparative reports can provide insight and opposing views regard-
ing perioperative outcomes and complications among procedures per-
formed by diverse groups of surgeons. Small trials comparing robotic-
assisted with laparoscopic and vaginal approaches have demonstrated
some bias in favor of non-robotic methods; surgeons in these trials
were highly experienced in laparoscopic and vaginal approaches but
had limited experience performing robotic hysterectomies [8–10]. To
date, comparative reports evaluating outcomes from robotic-assisted
benign hysterectomy procedures performed by experienced surgeons
are lacking. The aim of the present study was to addresses this gap by
evaluating perioperative outcomes from robotic-assisted hysterectomy
for benign disease performed by multiple gynecologic surgeons withElsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Trends in the proportion of hysterectomy procedures for benign indications
reported in the Premier Perspective database that were performed using robotic-
assisted, abdominal, laparoscopic, and vaginal approaches.
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these results to outcomes from vaginal, laparoscopic, and abdominal
hysterectomies for benign indications when performed by surgeons
experienced (≥60 surgeries) in these surgical approaches.
The purpose of the study was to contribute to the presently limited
literature of perioperative outcomes [11–13] from robotic-assisted
benign hysterectomy procedures, and to evaluate those outcomes
over the same period with outcomes from laparoscopic, abdominal,
and vaginal hysterectomies that had also been performed by high-
volume gynecologic surgeons.
2. Materials and methods
The present retrospective cohort study evaluated baseline, intra-
operative, and 30-day postoperative outcomes from multiport robotic-
assisted, abdominal, laparoscopic, and vaginal hysterectomies per-
formed for benign indications. All hysterectomies performed for benign
indications between January 1, 2010 and September 30, 2013 were in-
cluded and the only exclusion criterionwas the presence ofmalignancy.
The institutional review board of each study institution granted approv-
al or exemption for the study protocol and the need for informed con-
sent from patients was waived.
Data from robotic-assisted benign hysterectomies performed by
high-volume gynecologic surgeons who had completed at least 60
robotic-assisted benign hysterectomies prior to the study were includ-
ed. Experience of 60 surgeries was selected based on the reported
50–91 surgeries required to reach surgical proﬁciency in robotic-
assisted techniques [14,15]. The robotic-assisted surgeries were per-
formed at nine medical centers in the USA by a diverse group of seven
physicians with pelvic pain, oncology, urogynecology, and infertility
sub-specialties. Retrospective data were collected from the medical
records of all eligible patients at the surgeons' institutions and were
recorded by each institution's research coordinator in a validated
electronic database.
Data on abdominal, laparoscopic, and vaginal hysterectomies were
obtained from the Premier Perspective database and included all eligi-
ble patients with benign indications who underwent surgery during
the study period. The annual surgical case volume of benign hysterecto-
my procedures performed between 2008 and 2012 was used to deter-
mine high-volume experience for each surgeon who contributed to
the database. To be included in the analysis, surgeons had to haveperformed at least 60 surgeries in the respective approach prior to the
study period.
Data from the high-volume hysterectomy cohorts in the Premier da-
tabasewere available from hospitals throughout the USA. Patients were
identiﬁed using International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) procedure codes and patients had to
have 30-day follow-up data available to be included. Patient follow-up
data included age, presence of comorbid conditions (speciﬁcally, body
mass index [BMI calculated as weight in kilograms divided by the
square of height in meters] ≥40, the presence of adhesive disease, or
large uterus [N250 g]), indications for surgery, hysterectomy type and
concomitant procedures, conversion to open surgery, presence of intra-
operative and postoperative (≤30 days) complications, intraoperative
and postoperative blood transfusions, inpatient or outpatient designa-
tion, inpatient length of hospital stay, and hospital readmission or reop-
eration related to theprimary surgery through the 30-daypostoperative
follow-up period. Patients were considered to have adhesive disease if
patient records included a diagnosis of adhesive disease and/or if pelvic
and/or intra-abdominal adhesiolysis was performed at the time of the
hysterectomy. Current procedural terminology codes distinguishing
hysterectomies with uteri larger or smaller than 250 g were only avail-
able for vaginal and laparoscopic procedures.
Perioperative complications were determined by reviewing ICD-9-
CM diagnosis codes for morbidity not present on admission and were
classiﬁed as intraoperative or postoperative. Postoperative complications
were further categorized as having been surgical (including bleeding,
wound disruption, surgical-site infection, abscess, hematoma, seroma,
ﬁstula, postoperative prolapse of vaginal wall, incisional or port-site her-
nia, peripheral neuropathy), medical (including post-hemorrhagic ane-
mia, fever, adverse medication effects, dehydration, hypokalemia,
septicemia, shock, transfusion reactions), genitourinary (including
urinary retention, urinary tract infection, acute renal failure, hydro-
nephrosis, ureteric obstruction), gastrointestinal (including paralytic
ileus, nausea/vomiting, bowel obstruction), respiratory (including pul-
monary collapse, hypoxemia, pneumonia, pulmonary insufﬁciency,
acute respiratory failure, pleural effusion), thromboembolic events,
pain, cardiovascular (including cardiac arrhythmias, cardiac arrest,
acutemyocardial infarction), and central nervous system (including syn-
cope and collapse, altered consciousness/mental status, convulsions,
intracranial hemorrhage). Hemorrhage complications were deﬁned as
bleeding that complicated a procedure or that required a blood transfu-
sion. Necessitated reoperations were determined from a review of ICD-
9-CM procedure codes. Reoperation categories included repair of intra-
operative injury,wound repair/reconstruction, genitourinary and gastro-
intestinal procedures, control of hemorrhage and vascular procedures,
ﬁstula repair, and non-speciﬁc general exploratory or diagnostic surgery.
Data analyses were performed using SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA). Standard univariate methods were used to express
themean, standard deviation, and 95% conﬁdence intervals for continu-
ous variables. Discrete variableswere expressed as proportions and per-
centages and were compared using the χ2 test. Continuous variables
were compared using the Student t test. Tests for trends were per-
formed using the Jonckheere–Terpstra test. In all instances, two-sided
P b 0.05 was considered signiﬁcant.3. Results
Data were retrieved for 2300 eligible patients who underwent
robotic-assisted hysterectomy for benign indications at the nine institu-
tions during the study period. Patient data were obtained from 4 (44%)
teaching and 5 (56%) non-teaching hospitals. Patient records were re-
trieved for 9745 abdominal, 8121 vaginal, and 11 9521 laparoscopic
hysterectomies from the Premier Perspective database. The abdominal,
vaginal, and laparoscopic procedures were performed at 405 hospitals,
including 118 (29.1%) teaching and 287 (70.9%) non-teaching hospitals.
Table 1
Patient characteristics.a
Variable Robotic hysterectomy
(n = 2300)
Premier database hysterectomy procedures
Abdominal hysterectomy
(n = 9745)
Vaginal hysterectomy
(n = 8121)
Laparoscopic hysterectomy
(n = 11 952)
Age, y 49.3 ± 11.5 (48.8–49.7) 46.7 ± 10.7 (46.5–46.9) 48.7 ± 13.3 (48.4–49.0) 43.9 ± 9.4 (43.7–44.1)
P valueb Ref. b0.001 b0.001 b0.001
Morbid obesityc 181 (7.9) 884 (9.1) 250 (3.1) 446 (3.7)
P valued Ref. 0.074 b0.001 b0.001
Adhesive disease 431 (18.7) 2573 (26.4) 106 (1.3) 1427 (11.9)
P valued Ref. b0.001 b0.001 b0.001
Large uteruse 366 (15.9) 368 (3.8) 589 (7.3) 1671 (14.0)
P valued Ref. b0.001 b0.001 0.017
Surgical indicationsf
Abnormal uterine bleeding 1145 (49.8) 2444 (25.1) 2908 (35.8) 5246 (43.9)
Fibroids 758 (33.0) 4146 (42.5) 1201 (14.8) 3531 (29.5)
Endometriosis 335 (14.6) 842 (8.6) 454 (5.6) 1186 (9.9)
Prolapse 511 (22.2) 530 (5.4) 3320 (40.9) 796 (6.7)
Other 1011 (44.0) 2623 (26.9) 976 (12.0) 3189 (26.7)
P valued Ref. b0.001 b0.001 b0.001
a Values are given as mean ± SD (95% conﬁdence interval) or number (percentage), unless indicated otherwise.
b Student t test.
c Deﬁned as body mass index (calculated as weight in kilograms divided by the square of height in meters) ≥40.
d χ2 test.
e Deﬁned as N250 g.
f Surgical indications for each surgical approach do not total the number of patients included owing to patients having multiple surgical indications.
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indications for hysterectomy across all patients were abnormal uterine
bleeding and ﬁbroids. Patients who underwent robotic-assisted hyster-
ectomy were generally more complex; they were older, had higher
rates of adhesive disease, and had higher rates of large uteri than pa-
tients in the other cohorts. The robotic surgery patients also had a
higher rate of morbid obesity than the vaginal and laparoscopic cohorts
(Table 1).
Among the 2300 robotic-assisted hysterectomies, 1938 (84.3%)
were total hysterectomies (Table 2). Of the 9745 abdominal hysterecto-
mies, 9186 (94.3%) were total abdominal hysterectomies, and of the
11 952 laparoscopic hysterectomies, 5395 (45.1%) were laparoscopic-
assisted vaginal hysterectomies. A higher rate of concomitant proce-
dures, including pelvic-ﬂoor repair and reconstruction, was reported
in the robotic-assisted cohort (P b 0.001). Concomitant procedures per-
formed at the time of hysterectomy included adhesiolysis, cystoscopy,
endometriosis resection, hernia repair, appendectomy, cholecystecto-
my, bowel and colorectal procedures, and plastic and reconstructive
procedures (Table 2).Table 2
Procedures performed.a
Characteristics Robotic hysterectomy
(n = 2300)
Premi
Abdom
(n =
Procedure
Hysterectomy, NOS 0 0
Laparoscopic vaginal hysterectomy 0 0
Laparoscopic total abdominal hysterectomy 1938 (84.3) 0
Laparoscopic supracervical hysterectomy 362 (15.7) 0
Subtotal abdominal hysterectomy 0 560 (5
Total abdominal hysterectomy, NOS 0 9185
Vaginal hysterectomy, NOS 0 0
Patients undergoing concomitant procedures
None 366 (15.9) 1605
Adnexectomy only 423 (18.4) 3860
Pelvic ﬂoor repair/reconstruction 732 (31.8) 677 (6
Otherb 779 (33.9) 3603
P valuec Ref. b0.00
Abbreviation: NOS, not otherwise speciﬁed.
a Values are given as number (percentage) unless indicated otherwise.
b Patients who underwent concomitant procedures other than bilateral/unilateral salpingec
c χ2 test.The rates of conversion to open surgery were similar among the
robotic-assisted, vaginal, and laparoscopic cohorts (Table 3). Among
inpatients, the mean length of hospital stay was shorter for the
robotic-assisted group (1.37 days) than the open (3.0 days), vaginal
(1.9 days), and laparoscopic (1.7 days) groups (all P b 0.001). Overall,
patients undergoing robotic-assisted procedures experienced signiﬁ-
cantly fewer intraoperative complications (0.74%) compared with indi-
viduals in the abdominal (1.8%; P b 0.001) and vaginal (1.8%; P b 0.001)
cohorts, and fewer complications than patients in the laparoscopic
group (1.2%; P = 0.077); however, this difference was not signiﬁcant
(Table 4). No patients in the robotic-assisted group experienced intra-
operative hemorrhage, nerve injury, foreign bodies left in the peritoneal
cavity, mechanical failure, or medical accidents. Signiﬁcantly fewer pa-
tients in the robotic-assisted cohort required intraoperative blood trans-
fusions compared with patients in the abdominal (P b 0.001), vaginal
(P= 0.001), and laparoscopic (P= 0.011) cohorts.
Of the 2095 patients in the robotic-assisted cohortwith 30-day post-
operative data available, 131 (6.3%) experienced postoperative compli-
cations compared with 2047 (21.0%) patients in the abdominal cohort,er database hysterectomy procedures
inal hysterectomy
9745)
Vaginal hysterectomy
(n = 8121)
Laparoscopic hysterectomy
(n = 11 952)
0 0
0 5394 (45.1)
0 2131 (17.8)
0 4427 (37.0)
.7) 0 0
(94.3) 0 0
8121 (100.0) 0
(16.5) 2450 (30.2) 3812 (31.9)
(39.6) 1035 (12.7) 4286 (35.9)
.9) 1785 (22.0) 634 (5.3)
(37.0) 2851 (35.1) 3220 (26.9)
1 b0.001 b0.001
tomy/oophorectomy or pelvic ﬂoor repair/reconstruction.
Table 3
Perioperative outcomes.a
Perioperative outcome Robotic hysterectomy
(n = 2300)
Premier database hysterectomy procedures
Abdominal hysterectomy
(n = 9745)
Vaginal hysterectomy
(n = 8121)
Laparoscopic hysterectomy
(n = 11 952)
Conversion to open surgery 2 (0.1) NA 1 (0.0) 11 (0.1)
P valueb Ref. NA 0.243 N0.99
Inpatient length of hospital stay, d 1.37 ± 1.1 (1.31–1.43) 3.0 ± 1.6 (2.98–3.03) 1.9 ± 1.0 (1.86–1.96) 1.7 ± 1.2 (1.64–1.75)
P valuec Ref. b0.001 b0.001 b0.001
Abbreviation: NA, not applicable.
a Values are given as number (percentage) or mean ± SD (95% conﬁdence interval), unless indicated otherwise.
b χ2 test.
c Student t tests.
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cohort (all P b 0.001) (Table 5). Speciﬁcally, lower rates of medical,
cardiovascular, gastrointestinal, genitourinary, pain, central nervous
system, thromboembolic, and respiratory complications were recorded
in the robotic-assisted group. The postoperative blood transfusion rate
was signiﬁcantly lower in the robotic-assisted cohort compared with
the abdominal and vaginal cohorts, and was lower than in the laparo-
scopic cohort but this difference was not signiﬁcant. Signiﬁcantly
lower reoperation rates and hospital readmission rates were observed
in the robotic cohort compared with the abdominal cohort. The reoper-
ation and readmission rates were lower in the robotic-assisted cohort
than the vaginal and laparoscopic cohorts; however, this difference
was not signiﬁcant (Table 5).4. Discussion
The results of the present study provide compelling and valuable evi-
dence for the advantages of robotic-assisted hysterectomy for benign dis-
orders when performed by surgeons with high-volume experience
compared with laparoscopic, vaginal, or open abdominal hysterectomies
performed by high-volume surgeons. Improved clinical outcomes and
beneﬁts observed with robotic-assisted hysterectomies included a signif-
icantly lower postoperative complication rate compared with abdominal,
vaginal, and laparoscopic cohorts, despite the complexity of patients
being higher in the robotic-assisted cohort. Reductions in intraoperative
andpostoperative complications could translate to reductions in the over-
all economic burden of treatment, with reduced incidence of surgical or
medical injury correction, shorter hospitalization, fewer repeat surgeries,
shorter recovery with less pain, and less time lost from work or normal
activities, with concurrent improvements in quality of life.Table 4
Intraoperative complications.a
Intraoperative events Robotic hysterectomy
(n = 2300)
P
A
(
Patients experiencing any intraoperative complicationsb 17 (0.7) 1
P valuec Ref.
Hemorrhage 0
Laceration/puncture accident during surgery 16 (0.7) 1
Cautery/thermal injury 1 (0.0)
Nerve injury 0
Foreign body left in peritoneal cavity 0
Mechanical failure 0
Medical accident, not speciﬁed 0
Surgical, not speciﬁed 0
Patients requiring intraoperative blood transfusion 2 (0.1) 2
P valuec Ref.
Abbreviation: ICD-9-CM, International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁca
a Values are given as number (percentage) unless indicated otherwise.
b As deﬁned by ICD-9-CM codes.
c χ2 test.The present results contrast with reports of comparable clinical
outcomes between robotic-assisted hysterectomy and laparoscopic
or vaginal hysterectomy [1,6,10]. Conclusions from these studies
could be skewed, with outcomes from surgeonswhowere relatively in-
experienced in robotic-assisted gynecologic surgery being compared
with outcomes for established hysterectomy procedures performed by
high-volume laparoscopic surgeons. Sarlos et al. [2] and Paraiso et al.
[8] reported results from prospective randomized studies comparing
robotic-assisted surgery with laparoscopic surgery for benign disease,
demonstrating no differences in surgical outcomes and morbidity
[2,8]; the surgeons performing these procedures were highly experi-
enced laparoscopic surgeons but were early in their robotic-assisted
surgery learning curve.
Previous studies have analyzed surgical outcomes based on results
reported in the Premier Perspective database and the Nationwide Inpa-
tient Sample database [1,6,10]. Pasic et al. [1] andWright et al. [6] report-
ed data from 2007 to 2010, when surgeons were early in their learning
curve for robotic-assisted hysterectomy techniques [1,6]; in these stud-
ies, the non-robotically trainedminimally invasive gynecologic surgeons
were proﬁcient in laparoscopic surgery techniques. The results demon-
strated no signiﬁcant differences in perioperative clinical outcomes be-
tween robotic-assisted and laparoscopic procedures, although longer
operative times were reported for the robotic-assisted procedures.
The statistical difference reported in the present study in terms of
intraoperative complications, and postoperative medical, cardiovascular,
gastrointestinal, genitourinary, central nervous system, thromboembolic,
and respiratory complications favored the robotic approach over the ab-
dominal, laparoscopic, and vaginal approaches; although the difference
in intraoperative complication rates between the robotic and
laparoscopic approaches did not reach statistical signiﬁcance.
It is hypothesized that the signiﬁcant reductions in postoperativeremier database hysterectomy procedures
bdominal hysterectomy
n = 9745)
Vaginal hysterectomy
(n = 8121)
Laparoscopic hysterectomy
(n = 11 952)
74 (1.8) 142 (1.8) 142 (1.2)
b0.001 b0.001 0.077
66 (0.7) 62 (0.8) 43 (0.4)
05 (1.1) 79 (1.0) 99 (0.8)
0 2 (0.0) 1 (0.0)
0 3 (0.0) 0
1 (0.0) 3 (0.0) 2 (0.0)
0 0 1 (0.0)
66 (0.7) 45 (0.6) 58 (0.5)
6 (0.1) 1 (0.0) 2 (0.0)
07 (2.1) 61 (0.8) 58 (0.5)
b0.001 0.001 0.011
tion.
Table 5
Postoperative complications during 30-day follow-up.a
Events Robotic hysterectomy
(n = 2095)b
Premier database hysterectomy procedures
Abdominal hysterectomy
(n = 9745)
Vaginal hysterectomy
(n = 8121)
Laparoscopic hysterectomy
(n = 11 952)
Patients experiencing at least one postoperative complication 131 (6.3) 2047 (21.0) 1314 (16.2) 1953 (16.3)
P valuec Ref. b0.001 b0.001 b0.001
Surgical 72 (3.4) 751 (7.7) 318 (3.9) 371 (3.1)
Medical 8 (0.4) 684 (7.0) 296 (3.6) 337 (2.8)
Cardiovascular 2 (0.1) 151 (1.5) 126 (1.6) 166 (1.4)
Gastrointestinal 18 (0.9) 598 (6.1) 293 (3.6) 311 (2.6)
Genitourinary 37 (1.8) 384 (3.9) 402 (5.0) 479 (4.0)
Pain 9 (0.4) 354 (3.6) 241 (3.0) 647 (5.4)
Central nervous system 4 (0.2) 34 (0.3) 24 (0.3) 45 (0.4)
Thromboembolic 0 46 (0.5) 12 (0.1) 25 (0.2)
Respiratory 9 (0.4) 266 (2.7) 86 (1.1) 90 (0.8)
Patients requiring a postoperative blood transfusion 5 (0.2) 229 (2.3) 64 (0.8) 46 (0.4)
P valuec Ref. b0.001 0.005 0.298
Patients requiring hospital readmission related to index surgery 28 (1.3) 340 (3.5) 130 (1.6) 186 (1.6)
P valuec Ref. b0.001 0.218 0.259
Patients requiring reoperation related to index surgery 17 (0.8) 187 (1.9) 84 (1.0) 118 (1.0)
P valuec Ref. b0.001 0.248 0.314
a Values are given as number (percentage) unless indicated otherwise.
b 205 patients from the robotic-assisted cohort did not have complete 30-day follow-up data available and were excluded from the analysis.
c χ2 test.
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cations are attributable to the combination of the robotic technologywith
surgical experience and proﬁciency in this approach. Rosero et al. [10] re-
ported a higher incidence of pneumonia among patients treated with ro-
botic surgery when conducted by surgeons with varying levels of
proﬁciency [10]. Inexperience can lead to prolonged operative times,
resulting in increased postoperative complications [16]. The present
study demonstrated a lower rate of respiratory complications and this
could be attributed, in part, to a mean operative (skin-to-skin) time of
1.7±0.7 h. This compares favorably to operative times reported in the lit-
erature for vaginal, total laparoscopic, and laparoscopic-assisted vaginal
hysterectomies [17,18]. Skin-to-skin times were not available from the
Premier database, which only reported the time from when the patient
entered the operating room to when they exited. The times reported
were 2.5 ± 1.2 h, 2.2 ± 1.0 h, and 2.7 ± 1.2 h in the abdominal, vaginal,
and laparoscopic cohorts, respectively. Although it is not possible to com-
pare the surgical time and operating-room time directly, themean differ-
ence between the robotic-assisted cohort and the laparoscopic cohortwas
1.0 h. Inefﬁciencies in the operating room and differences in preparation
times could have contributed to this difference.
The effect of surgical volume on clinical outcomes is highly relevant to
the interpretation of the present study data. Signiﬁcantly improved clini-
cal outcomes can be expected from surgeons with high-volume experi-
ence. Lenihan et al. [14] reported that a learning curve of 50 surgical
cases was necessary to stabilize the operating time for robotic-assisted
hysterectomies [14]. According to Woelk et al. [15], reduced intraopera-
tive morbidity is the primary factor deﬁning surgical proﬁciency,
which—in their study comparing robotic-assisted hysterectomy to ab-
dominal hysterectomy—was reached after completing 91 procedures [15].
The robotic-assisted cohort in the present study experienced fewer
intraoperative complications and signiﬁcantly fewer postoperative com-
plications compared with the non-robotic surgery groups. These results
are similar, especially the postoperative complication rates, to those
reported by Lönnerfors et al. [19] in a randomized, controlled trial
that evaluated the outcomes from high-volume surgeons performing
robotic-assisted, laparoscopic, and vaginal hysterectomy [19].
The strengths of the present study included the rigorous, methodi-
cal, and detailed analyses of 2300 consecutive patients who underwent
robotic-assisted hysterectomy in nine hospitals within the USA.
Most published studies of robotic-assisted hysterectomy outcomes in-
volve smaller numbers of patients or are single-center studies [20–22].The present analysis included granularity regarding intraoperative
and postoperative complications. That the present study included
only high-volume gynecologic surgeons across all cohorts speaks to
the favorable outcomes that are possible with proﬁciency in robotic-
assisted techniques.
The retrospective nature of these comparisons is a limitation. Addi-
tionally, the Premier database relies on ICD-9-CM diagnostic and proce-
dure codes, with potential for miscoding. Readmission data could have
been lost for patients if they were readmitted to non-Premier member
hospitals, resulting in potential under-reporting. The designation of
high-volume experience in Premier could be conservative; Premier sur-
geons could have had a greater degree of experience than60 procedures
if they had performed surgeries at non-Premier hospitals or they per-
formed more procedures prior to the period analyzed. Additionally,
postoperative follow-up information following discharge was missing
for 205 patients treated by one surgeon using the robotic-assisted
approach; missing data is a common inherent limitation of retrospec-
tive data collection. Finally, the length of stay for outpatients was
not available in the Premier database. Patients in the robotic-assisted
cohort were categorized as outpatients if they were hospitalized for
less than 24 h; however, patients in the other cohorts could have been
observed in the hospital for up to 72 h and still been designated as
outpatients.
The present study contains a detailed examination of clinical out-
comes from the largest series of robotic-assisted benign hysterectomy
patients reported in the literature. The costliness of robotic-assisted
hysterectomy has previously been reported [1] without consideration
of the perioperative outcomes from procedures performed by surgeons
with comparable levels of experience. Consequently, an economic
analysis is currently underway. Gynecologic surgeons with high-
volume experience with robotic-assisted hysterectomies could offer
patients clear beneﬁts and potentially achieve signiﬁcantly improved
perioperative clinical outcomes compared with gynecologic surgeons
who have high-volume experience of performing open, laparoscopic,
or vaginal hysterectomies.Acknowledgments
Intuitive Surgical Inc. provided funding for independent research
and editorial support.
364 P.C. Lim et al. / International Journal of Gynecology and Obstetrics 133 (2016) 359–364Conﬂicts of Interest
P.C.L., J.T.C., D.M.G., and M.L.W. proctor da Vinci Surgical System
advanced surgical courses. Intuitive Surgical Inc. provided funding for
the present study and editorial support.References
[1] Pasic RP, Rizzo JA, Fang H, Ross S, MooreM, Gunnarsson C. Comparing robot-assisted
with conventional laparoscopic hysterectomy: impact on cost and clinical outcomes.
J Minim Invasive Gynecol 2010;17(6):730–8.
[2] Sarlos D, Kots L, Stevanovic N, von Felten S, Schär G. Robotic compared with conven-
tional laparoscopic hysterectomy: a randomized controlled trial. Obstet Gynecol
2012;120(3):604–11.
[3] Scandola M, Grespan L, Vicentini M, Fiorini P. Robot-assisted laparoscopic hysterec-
tomy vs traditional laparoscopic hysterectomy: ﬁve metaanalyses. J Minim Invasive
Gynecol 2011;18(6):705–15.
[4] Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Nationwide use of
laparoscopic hysterectomy compared with abdominal and vaginal approaches.
Obstet Gynecol 2009;114(5):1041–8.
[5] Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG. Hysterectomy rates in the
United States, 2003. Obstet Gynecol 2007;110(5):1091–5.
[6] Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, et al. Robotically
assisted vs laparoscopic hysterectomy among women with benign gynecologic
disease. JAMA 2013;309(7):689–98.
[7] Advincula AP, Song A. The role of robotic surgery in gynecology. Curr Opin Obstet
Gynecol 2007;19(4):331–6.
[8] Paraiso MF, Ridgeway B, Park AJ, Jelovsek JE, Barber MD, Falcone T, et al. A random-
ized trial comparing conventional and robotically assisted total laparoscopic hyster-
ectomy. Am J Obstet Gynecol 2013;208(5):368.e1–7.
[9] Kilic GS, Moore G, Elbatanony A, Radecki C, Phelps JY, Borahay MA. Comparison of
Perioperative Outcomes of Total Laparoscopic and Robotically Assisted Hysterectomy
for Benign Pathology during Introduction of a Robotic Program. Obstet Gynecol Int
2011;2011:683703.[10] Rosero EB, Kho KA, Joshi GP, Giesecke M, Schaffer JI. Comparison of robotic and lap-
aroscopic hysterectomy for benign gynecologic disease. Obstet Gynecol 2013;
122(4):778–86.
[11] Luciano AA, Luciano DE, Gabbert J, Seshadri-Kreaden U. The impact of robotics on
the mode of benign hysterectomy and clinical outcomes. Int J Med Robot 2015.
http://dx.doi.org/10.1002/rcs.1648.
[12] Lim PC, Kang E. Park do H. A comparative detail analysis of the learning curve and
surgical outcome for robotic hysterectomy with lymphadenectomy versus laparo-
scopic hysterectomy with lymphadenectomy in treatment of endometrial cancer:
a case-matched controlled study of the ﬁrst one hundred twenty two patients.
Gynecol Oncol 2011;120(3):413–8.
[13] Gala RB, Margulies R, Steinberg A, Murphy M, Lukban J, Jeppson P, et al. Systematic
review of robotic surgery in gynecology: robotic techniques compared with laparos-
copy and laparotomy. J Minim Invasive Gynecol 2014;21(3):353–61.
[14] Lenihan Jr JP, Kovanda C, Seshadri-Kreaden U. What is the learning curve for robotic
assisted gynecologic surgery? J Minim Invasive Gynecol 2008;15(5):589–94.
[15] Woelk JL, Casiano ER, Weaver AL, Gostout BS, Trabuco EC, Gebhart JB. The learning
curve of robotic hysterectomy. Obstet Gynecol 2013;121(1):87–95.
[16] Owen RM, Perez SD, Lytle N, Patel A, Davis SS, Lin E, et al. Impact of operative dura-
tion on postoperative pulmonary complications in laparoscopic versus open
colectomy. Surg Endosc 2013;27(10):3555–63.
[17] Orady M, Hrynewych A, Nawfal AK, Wegienka G. Comparison of robotic-assisted
hysterectomy to other minimally invasive approaches. JSLS 2012;16(4):542–8.
[18] Geller EJ, Lin FC, Matthews CA. Analysis of robotic performance times to improve
operative efﬁciency. J Minim Invasive Gynecol 2013;20(1):43–8.
[19] Lönnerfors C, Reynisson P, Persson J. A randomized trial comparing vaginal and lap-
aroscopic hysterectomy vs robot-assisted hysterectomy. J Minim Invasive Gynecol
2015;22(1):78–86.
[20] Sarlos D, Kots L, Stevanovic N, Schaer G. Robotic hysterectomy versus conventional
laparoscopic hysterectomy: outcome and cost analyses of a matched case–control
study. Eur J Obstet Gynecol Reprod Biol 2010;150(1):92–6.
[21] Nezhat C, Lavie O, Lemyre M, Gemer O, Bhagan L, Nezhat C. Laparoscopic hysterec-
tomy with and without a robot: Stanford experience. JSLS 2009;13(2):125–8.
[22] Patzkowsky KE, As-Sanie S, Smorgick N, Song AH, Advincula AP. Perioperative out-
comes of robotic versus laparoscopic hysterectomy for benign disease. JSLS 2013;
17(1):100–6.
